Shareholders Equity: The sum of preferred and common equity items.
Kalaris Therapeutics Inc. (KLRS) had Shareholders Equity of $63.87M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-10.20M |
|
-- |
|
-- |
|
$10.35M |
|
$-10.35M |
|
$0.16M |
|
$-10.20M |
|
$-10.20M |
|
$-10.20M |
|
$-10.20M |
|
$-10.20M |
|
$-10.20M |
|
$-10.35M |
|
$-10.35M |
|
4.05M |
|
4.05M |
|
$-2.52 |
|
$-2.52 |
|
| Balance Sheet Financials | |
$102.18M |
|
-- |
|
$0.91M |
|
$103.09M |
|
$7.14M |
|
-- |
|
$32.08M |
|
$39.22M |
|
$63.87M |
|
$63.87M |
|
|
Shareholders Equity |
$63.87M |
18.70M |
|
| Cash Flow Statement Financials | |
$-7.44M |
|
-- |
|
$107.27M |
|
$1.64M |
|
$101.47M |
|
$99.83M |
|
$0.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.44M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.96% |
|
-15.96% |
|
-9.89% |
|
-15.96% |
|
$3.42 |
|
$-1.84 |
|
$-1.84 |
|